License & Collaboration Revenue was Vir Biotechnology’s largest product and service line in fiscal 2025, bringing in $63.13M of $68.56M (92%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Collaboration Revenue | $1.51B | — | — | — | |
| Contract Revenue | $52.71M | — | — | — | |
| License & Collaboration Revenue | — | $37.38M | $61.37M | $63.13M | |
| License Revenue From A Related Party | $22.30M | — | — | — | |
| Grant Revenue | $35.33M | $46.69M | $10.49M | $2.04M | |
| Other Revenue | — | $2.11M | $2.34M | $3.39M | |
| Total | $1.62B | $86.18M | $74.21M | $68.56M |
Vir Biotechnology brought in $68.56M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 7.6% from $74.21M in fiscal 2024. License & Collaboration Revenue was the largest at $63.13M (92.1%), ahead of Other Revenue at $3.39M (4.9%) and Grant Revenue at $2.04M (3.0%).
Compared with fiscal 2024, Other Revenue grew fastest, up 44.7% to $3.39M, while Grant Revenue fell the most, down 80.6% to $2.04M.
Vir Biotechnology began breaking out License & Collaboration Revenue in fiscal 2023 and Other Revenue in fiscal 2023. Vir Biotechnology stopped reporting Collaboration Revenue ($1.51B in fiscal 2022), Contract Revenue ($52.71M in fiscal 2022) and License Revenue From A Related Party ($22.30M in fiscal 2022) as separate lines.
Vir Biotechnology (VIR) reports its revenue by product and service. In fiscal 2025, License & Collaboration Revenue was its largest product and service line, bringing in $63.13M (92.1% of the total), followed by Other Revenue at $3.39M (4.9%).
License & Collaboration Revenue was Vir Biotechnology's largest product and service line in fiscal 2025, bringing in $63.13M, or 92.1% of the $68.56M total across its three product and service lines.
Among Vir Biotechnology's product and service lines that make up at least 2% of revenue, Other Revenue grew fastest in fiscal 2025, up 44.7% from $2.34M to $3.39M.
Every figure comes from Vir Biotechnology's annual financial filings, as reported. Each line keeps the name Vir Biotechnology gives it, and years follow its fiscal calendar.
Vir Biotechnology's revenue by product and service goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.